The FDA is preparing to use real-time clinical trial data review in oncology, starting with studies from Amgen and AstraZeneca. The agency’s approach aims to reduce the lag between trial conduct and the availability of trial data for regulatory evaluation, building on proof-of-concept work the FDA previously piloted with the companies.